Table 1.
Population basal characteristics.
| Variable | N (Total = 55) | % |
|---|---|---|
| Sex | ||
| Female | 16 | 29.10% |
| Male | 39 | 70.90% |
| Age | ||
| <75 years | 47 | 85% |
| >75 years | 8 | 15% |
| Smoking habit | ||
| Never smoker | 2 | 3.60% |
| Former smoker/Current smoker | 53 | 96.40% |
| ECOG | ||
| ECOG 0 | 36 | 65.50% |
| ECOG 1 | 19 | 34.50% |
| Histology | ||
| Squamous | 22 | 40% |
| Adenocarcinomas | 33 | 60% |
| Tumor stage | ||
| Stage III | 16 | 29.10% |
| Stage IV | 39 | 70.90% |
| Treatment indication | ||
| Locally advanced | 14 | 25.50% |
| First line | 18 | 32.70% |
| Second line or more | 23 | 41.80% |
| ICI drug | ||
| Durvalumab | 14 | 25.50% |
| Pembrolizumab | 21 | 38.20% |
| Atezolizumab | 18 | 32.70% |
| Nivolumab | 2 | 3.60% |
| Objective Response | ||
| Complete response | 10 | 18.80% |
| Partial response | 13 | 23.60% |
| Stable disease | 12 | 21.8% |
| Progressive disease | 15 | 27.30% |
| Not evaluable | 5 | 9.10% |
| LDH | 36.40% | |
| High (>202U/L) | 20 | 36.40% |
| Normal (<202U/L) | 35 | 63.60% |
| PD-L1 | ||
| <1% | 10 | 18.20% |
| 1–49% | 21 | 38.20% |
| >50% | 16 | 29.10% |
| Unknow | 8 | 14.50% |
ECOG: Eastern Cooperative Oncology Group; ICI: Immune Checkpoint Inhibitor; LDH: Lactate Dehydrogenase.